No link between type I interferon autoantibody positivity and adverse reactions to COVID-19 vaccines
Abstract Type I interferons act as gatekeepers against viral infection, and autoantibodies that neutralize these signaling molecules have been associated with COVID-19 severity and adverse reactions to the live-attenuated yellow fever vaccine. On this background, we sought to examine whether autoant...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-02-01
|
| Series: | npj Vaccines |
| Online Access: | https://doi.org/10.1038/s41541-024-00829-9 |
| _version_ | 1797276024323440640 |
|---|---|
| author | Ahmet Yalcinkaya Marco Cavalli Axel Cederholm Maribel Aranda-Guillén Anish Behere Hedvig Mildner Tadepally Lakshmikanth Laura Gonzalez Constantin Habimana Mugabo Anette Johnsson Olov Ekwall Olle Kämpe Sophie Bensing Petter Brodin Pär Hallberg Mia Wadelius Nils Landegren |
| author_facet | Ahmet Yalcinkaya Marco Cavalli Axel Cederholm Maribel Aranda-Guillén Anish Behere Hedvig Mildner Tadepally Lakshmikanth Laura Gonzalez Constantin Habimana Mugabo Anette Johnsson Olov Ekwall Olle Kämpe Sophie Bensing Petter Brodin Pär Hallberg Mia Wadelius Nils Landegren |
| author_sort | Ahmet Yalcinkaya |
| collection | DOAJ |
| description | Abstract Type I interferons act as gatekeepers against viral infection, and autoantibodies that neutralize these signaling molecules have been associated with COVID-19 severity and adverse reactions to the live-attenuated yellow fever vaccine. On this background, we sought to examine whether autoantibodies against type I interferons were associated with adverse events following COVID-19 vaccination. Our nationwide analysis suggests that type I interferon autoantibodies were not associated with adverse events after mRNA or viral-vector COVID-19 vaccines. |
| first_indexed | 2024-03-07T15:22:23Z |
| format | Article |
| id | doaj.art-ec0a193a12544f03967d6f45840767f0 |
| institution | Directory Open Access Journal |
| issn | 2059-0105 |
| language | English |
| last_indexed | 2024-03-07T15:22:23Z |
| publishDate | 2024-02-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Vaccines |
| spelling | doaj.art-ec0a193a12544f03967d6f45840767f02024-03-05T17:36:59ZengNature Portfolionpj Vaccines2059-01052024-02-01911610.1038/s41541-024-00829-9No link between type I interferon autoantibody positivity and adverse reactions to COVID-19 vaccinesAhmet Yalcinkaya0Marco Cavalli1Axel Cederholm2Maribel Aranda-Guillén3Anish Behere4Hedvig Mildner5Tadepally Lakshmikanth6Laura Gonzalez7Constantin Habimana Mugabo8Anette Johnsson9Olov Ekwall10Olle Kämpe11Sophie Bensing12Petter Brodin13Pär Hallberg14Mia Wadelius15Nils Landegren16Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala UniversityDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala UniversityDepartment of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala UniversityCenter for Molecular Medicine, Department of Medicine (Solna), Karolinska InstitutetDepartment of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala UniversityDepartment of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala UniversityDepartment of Women’s and Children’s Health, Karolinska InstitutetDepartment of Women’s and Children’s Health, Karolinska InstitutetDepartment of Women’s and Children’s Health, Karolinska InstitutetDepartment of Women’s and Children’s Health, Karolinska InstitutetDepartment of Pediatrics, Institute of Clinical Sciences, The Sahlgrenska Academy at University of GothenburgCenter for Molecular Medicine, Department of Medicine (Solna), Karolinska InstitutetDepartment of Endocrinology, Karolinska University HospitalDepartment of Women’s and Children’s Health, Karolinska InstitutetDepartment of Medical Sciences, Clinical Pharmacogenomics, Science for Life Laboratory, Uppsala UniversityDepartment of Medical Sciences, Clinical Pharmacogenomics, Science for Life Laboratory, Uppsala UniversityDepartment of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala UniversityAbstract Type I interferons act as gatekeepers against viral infection, and autoantibodies that neutralize these signaling molecules have been associated with COVID-19 severity and adverse reactions to the live-attenuated yellow fever vaccine. On this background, we sought to examine whether autoantibodies against type I interferons were associated with adverse events following COVID-19 vaccination. Our nationwide analysis suggests that type I interferon autoantibodies were not associated with adverse events after mRNA or viral-vector COVID-19 vaccines.https://doi.org/10.1038/s41541-024-00829-9 |
| spellingShingle | Ahmet Yalcinkaya Marco Cavalli Axel Cederholm Maribel Aranda-Guillén Anish Behere Hedvig Mildner Tadepally Lakshmikanth Laura Gonzalez Constantin Habimana Mugabo Anette Johnsson Olov Ekwall Olle Kämpe Sophie Bensing Petter Brodin Pär Hallberg Mia Wadelius Nils Landegren No link between type I interferon autoantibody positivity and adverse reactions to COVID-19 vaccines npj Vaccines |
| title | No link between type I interferon autoantibody positivity and adverse reactions to COVID-19 vaccines |
| title_full | No link between type I interferon autoantibody positivity and adverse reactions to COVID-19 vaccines |
| title_fullStr | No link between type I interferon autoantibody positivity and adverse reactions to COVID-19 vaccines |
| title_full_unstemmed | No link between type I interferon autoantibody positivity and adverse reactions to COVID-19 vaccines |
| title_short | No link between type I interferon autoantibody positivity and adverse reactions to COVID-19 vaccines |
| title_sort | no link between type i interferon autoantibody positivity and adverse reactions to covid 19 vaccines |
| url | https://doi.org/10.1038/s41541-024-00829-9 |
| work_keys_str_mv | AT ahmetyalcinkaya nolinkbetweentypeiinterferonautoantibodypositivityandadversereactionstocovid19vaccines AT marcocavalli nolinkbetweentypeiinterferonautoantibodypositivityandadversereactionstocovid19vaccines AT axelcederholm nolinkbetweentypeiinterferonautoantibodypositivityandadversereactionstocovid19vaccines AT maribelarandaguillen nolinkbetweentypeiinterferonautoantibodypositivityandadversereactionstocovid19vaccines AT anishbehere nolinkbetweentypeiinterferonautoantibodypositivityandadversereactionstocovid19vaccines AT hedvigmildner nolinkbetweentypeiinterferonautoantibodypositivityandadversereactionstocovid19vaccines AT tadepallylakshmikanth nolinkbetweentypeiinterferonautoantibodypositivityandadversereactionstocovid19vaccines AT lauragonzalez nolinkbetweentypeiinterferonautoantibodypositivityandadversereactionstocovid19vaccines AT constantinhabimanamugabo nolinkbetweentypeiinterferonautoantibodypositivityandadversereactionstocovid19vaccines AT anettejohnsson nolinkbetweentypeiinterferonautoantibodypositivityandadversereactionstocovid19vaccines AT olovekwall nolinkbetweentypeiinterferonautoantibodypositivityandadversereactionstocovid19vaccines AT ollekampe nolinkbetweentypeiinterferonautoantibodypositivityandadversereactionstocovid19vaccines AT sophiebensing nolinkbetweentypeiinterferonautoantibodypositivityandadversereactionstocovid19vaccines AT petterbrodin nolinkbetweentypeiinterferonautoantibodypositivityandadversereactionstocovid19vaccines AT parhallberg nolinkbetweentypeiinterferonautoantibodypositivityandadversereactionstocovid19vaccines AT miawadelius nolinkbetweentypeiinterferonautoantibodypositivityandadversereactionstocovid19vaccines AT nilslandegren nolinkbetweentypeiinterferonautoantibodypositivityandadversereactionstocovid19vaccines |